Mallia

Mallia Innovations GmbH is the holding company strategically driving the development and commercialization of cosmetic applications and biopharmaceutical therapies of the immune modulatory sCD83 protein, targeting hair growth, hair loss and other dermatological indications, including wound healing. Subsidiary Mallia Aesthetics GmbH focuses on the development of cosmetic products to stimulate hair growth. Subsidiary Mallia Therapeutics GmbH focuses on the clinical development of novel therapies for patients suffering from androgenetic alopecia or alopecia areata, among other conditions.